Percutaneous endoscopic gastrostomy (PEG) is a method widely used for patients with amyotrophic lateral sclerosis (ALS); nevertheless, its effect on survival remains unclear. The purpose of this meta-analysis study was to determine the effects of PEG on survival in ALS patients. Relevant studies were retrieved from PubMed, EmBase, and the Cochrane Library databases, from inception to June 2017. Studies comparing PEG with other procedures in ALS patients were included. Odds ratios (ORs) in a random-effects model were used to assess the survival at different follow-up periods. Briefly, ten studies involving a total of 996 ALS patients were included. Summary ORs indicated that PEG administration was not associated with 30-day (OR = 1.59; 95%CI 0.93-2.71; P = 0.092), 10-month (OR = 1.25; 95%CI 0.72-2.17; P = 0.436), and 30-month (OR = 1.28; 95% CI 0.77-2.11; P = 0.338) survival rates, while they showed a beneficial effect in 20-month survival rate (OR = 1.97; 95%CI 1.21-3.21; P = 0.007). The survival rate was significantly prominent in reports published before 2005, and in studies with a retrospective design, sample size <100, mean age <60.0 years, and percentage male ≥50.0%. To sum up, these findings suggested that ALS patients administered with PEG had an increased 20-month survival rates, while there was no significant effect in 30-day, 10-month, and 30-month survival rates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800689 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0192243 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Hypothalamic atrophy in primary lateral sclerosis, assessed by convolutional neural network-based automatic segmentation.
Sci Rep
January 2025
Dept. of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Primary lateral sclerosis (PLS) is a motor neuron disease (MND) which mainly affects upper motor neurons. Within the MND spectrum, PLS is much more slowly progressive than amyotrophic laterals sclerosis (ALS). `Classical` ALS is characterized by catabolism and abnormal energy metabolism preceding onset of motor symptoms, and previous studies indicated that the disease progression of ALS involves hypothalamic atrophy.
View Article and Find Full Text PDFNew biofluid measures for TDP‐43.
Alzheimers Dement
December 2024
UK Dementia Research Institute at University College London, London, United Kingdom; Dementia Research Centre at University College London, London, United Kingdom
Transactive response DNA‐binding protein 43 (TDP‐43) has emerged as a pivotal player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and the recently described limbic‐predominant age‐related TDP‐43 encephalopathy (LATE). Detecting TDP‐43 pathology in a minimally invasive manner is crucial for early diagnosis, monitoring disease progression and the assessment of therapeutic interventions. This talk explores recent advancements in the discovery and validation of novel biofluid measures aimed at detecting and characterising TDP‐43 pathology.
View Article and Find Full Text PDFThe Global Neurodegeneration Proteomics Consortium ‐ Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging.
Alzheimers Dement
December 2024
Gates Ventures, Seattle, WA, USA
Background: Limited understanding of biological mechanisms behind the onset and progression of Neurodegenerative Disorders has been a burden for the discovery of novel biomarkers and treatments. Large, harmonized, patient‐derived datasets will be key in unraveling the complex biology leading to neurodegeneration. The Global Neurodegeneration Proteomics Consortium (GNPC) is a major biomarker discovery effort to unite and expand the available proteomic data for thousands of patient samples from leading dementia cohorts from around the world and comprises, to our knowledge, the largest discovery proteomics dataset to date.
View Article and Find Full Text PDFReversal of mutation‐induced transcriptional dysregulation and pathology in cultured human neurons by allele‐specific excision.
Alzheimers Dement
December 2024
UCSF Weill Institute for Neurosciences, San Francisco, CA, USA
Background: Efforts to genetically reverse C9orf72 pathology have been hampered by our incomplete understanding of the regulation of this complex locus.
Method: We generated five different genomic excisions at the locus in a patient‐derived iPSC line and a WT line (11 total isogenic lines), and examined gene expression and pathological hallmarks of C9 FTD/ALS in motor neurons differentiated from these lines. Comparing the excisions in these isogenic series removed the confounding effects of different genomic backgrounds and allowed us to probe the effects of specific genomic changes.
Riluzole is associated with reduced risk of heart failure.
Eur J Neurol
January 2025
Department of Pharmacotherapy, University of Utah Health, Salt Lake City, Utah, USA.
Background: Reduction of intracellular Na accumulation through late Na current inhibition has been recognized as a target for cardiac Ca handling which underlies myocardial contractility and relaxation in heart failure (HF). Riluzole, an Na channel blocker with enhancement of Ca-activated K channel function, used for management of amyotrophic lateral sclerosis (ALS), is effective in suppressing Ca leak and therefore may improve cardiac function.
Objectives: The study aim was to investigate whether riluzole lowers HF incidence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!